BioCentury
ARTICLE | Clinical News

FDA approves Novo Nordisk's subcutaneous Ozempic semaglutide for diabetes

December 8, 2017 4:16 AM UTC

FDA approved subcutaneous Ozempic semaglutide from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) as an adjunct to diet and exercise to improve glycemic control in adults with Type II diabetes.

Novo Nordisk plans to launch the long-acting glucagon-like peptide-1 (GLP-1) analog in the U.S. next quarter. The company told BioCentury that the expected wholesale acquisition cost (WAC) is $676 for four to six weeks of once-weekly treatments, depending on the patient's titrated maintenance dose. According to the U.S. label, patients may increase their maintenance dose from 0.5 mg once weekly to 1 mg once weekly if additional glycemic control is needed after at least four weeks...